Treatment
Gemcitabine clinical trials
We’re tracking 378 recruiting studies that include Gemcitabine, each written for real people, not researchers, below.
Recruiting studies
- NCT07436741RecruitingPhase 3
Study of surufatinib plus chemo before surgery for pancreatic cancer
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05305131RecruitingPhase 2
Testing chemotherapy with or without extra cancer medicines for nasopharyngeal cancer
This Phase 2 study compares standard chemotherapy (gemcitabine plus cisplatin) against the same chemotherapy plus pembrolizumab and bevacizumab. It aims to see which combination works better for EBV-positive nasopharyngeal cancer before any prior treatment.
SingaporeAges 1.8 years–99 years - NCT06214572RecruitingPhase 2/Phase 3
Radiation Therapy for Advanced Gallbladder Cancer
This trial tests a type of radiation therapy for people with advanced gallbladder cancer that cannot be removed by surgery. It is for those whose cancer has not spread to other parts of the body and has stayed stable or improved after initial chemotherapy.
Mumbai, MaharashtraAges 18 years+ - NCT06361888RecruitingPhase 2/Phase 3
Testing a new drug combo for advanced pancreatic cancer
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
Nanjing, JiangsuAges 18–75 - NCT03257033RecruitingPhase 3
Gemcitabine through an artery versus by vein after radiation
This study tests whether giving gemcitabine directly into the artery feeding the pancreas (instead of through an IV) works better after you finish radiation therapy. It may help patients by improving how the medicine reaches the tumor while comparing side effects and outcomes between the two delivery methods.
Loma Linda, CaliforniaAges 18 years+ - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT05823311RecruitingPhase 3
Test lenvatinib and immunotherapy plus chemo for bile duct cancer
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
Hangzhou, ZhejiangAges 18–75 - NCT06229496RecruitingPhase 1
Study of GAS for newly diagnosed advanced pancreatic cancer
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
Chiayi CityAges 18 years+ - NCT05653453RecruitingPhase 3
Tumor treatment device plus chemo for locally advanced pancreatic cancer
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Harbin, HeilongjiangAges 18–75 - NCT07662018Recruiting
Study of stem cell transplant after chemo for children with germ cell tumors
This study looks at how well a stem cell transplant works after a specific combination of chemotherapy drugs (gemcitabine, docetaxel, melphalan, and carboplatin) in children and young adults up to age 21 whose germ cell tumors have come back or not responded to treatment. It may help doctors understand who benefits most from this approach.
Houston, TexasAges 21 years+ - NCT06521255RecruitingPhase 3
New drug combo vs standard for relapsed DLBCL
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
BeijingAges 18 years+ - NCT06156514RecruitingPhase 3
Comparing chemo drugs with radiation for advanced cervical cancer
This trial compares two chemotherapy drugs (cisplatin vs. gemcitabine) given together with radiation therapy for locally advanced cervical cancer. The goal is to see which is more effective and has fewer side effects.
Mexico City, Mexico CityAges 18 years+ - NCT07747740RecruitingPhase 2
Bladder cancer treatment after BCG therapy fails
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
Moscow, MoscowAges 18 years+ - NCT04947059RecruitingPhase 3
Stop bladder cancer coming back with medicine after bladder surgery
This trial tests whether putting chemotherapy medicine directly into the bladder right after surgery helps prevent bladder cancer from coming back. It compares gemcitabine versus epirubicin given as an immediate bladder “wash-in.”
Larissa, Larissa/ThessalyAges 18–100 - NCT05532059RecruitingPhase 2
Test lenvatinib, tislelizumab, and chemotherapy for bile duct cancer
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hangzhou, ZhejiangAges 18–85 - NCT06235203RecruitingPhase 3
Comparing treatment timing in recurrent nasopharyngeal cancer
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06953999RecruitingPhase 3
Testing immunotherapy plus chemo for metastatic pancreatic cancer
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Harbin, HeilongjiangAges 18–75 - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT05314998RecruitingPhase 3
Chemo after fully removed pancreatic cancer, guided by gene testing
This Phase 3 study tests whether people with pancreatic cancer should get standard chemo or a chemo plan guided by a tumor gene/RNA test after surgery. It aims to see if the right chemo choice for your tumor biology can improve outcomes after your tumor is removed.
AachenAges 18–79 - NCT07158489RecruitingPhase 2
New drug combo for advanced lung cancer after immunotherapy
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
BadenAges 18 years+ - NCT06923475RecruitingPhase 2/Phase 3
Chemo plus immunotherapy before surgery for bile duct cancer
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
AmsterdamAges 18 years+ - NCT07129993RecruitingPhase 2/Phase 3
Study of datopotamab deruxtecan with chemo for advanced bladder cancer
This trial is testing a new drug combination for advanced bladder cancer that has grown despite previous treatment. It pairs a targeted therapy (datopotamab deruxtecan) with chemotherapy, and the goal is to see if it can slow down or stop the cancer better than standard chemo alone.
Fullerton, CaliforniaAges 18 years+ - NCT07259317RecruitingPhase 2
Relacorilant plus chemo for metastatic pancreatic cancer
This trial tests adding a drug called relacorilant to standard chemotherapy (nab-paclitaxel and gemcitabine) for people with pancreatic cancer that has spread. The goal is to see if this combination works better than chemo alone.
Scottsdale, ArizonaAges 18 years+ - NCT05126472RecruitingPhase 1/Phase 2
Study of 2141-V11 for bladder cancer that did not respond to standard treatment
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Basking Ridge, New JerseyAges 18 years+
What Gemcitabine is being studied for
Conditions with recruiting Gemcitabine studies.
Common questions
- Are there clinical trials studying Gemcitabine?
- Yes. Clin2 currently lists 378 recruiting studies that include Gemcitabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Gemcitabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Gemcitabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Gemcitabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.